AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03043482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple VS-105/placebo to HD subjects
Description: In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
Study NCT00005624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-994
Description: CI-994 as outlined in treatment arm.
Study NCT03409120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Vercise PC IPG with directional DBS lead
Description: We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
Study NCT00546741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, once daily single dose
Study NCT00546741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablets, Oral, 1000 mg, once daily, single dose
Study NCT00546741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin + Metformin
Description: Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg
Study NCT01912352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Study NCT02810015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
Study NCT04174937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potentiator of antibiotics (PA)
Description: Intervention is administered to patients in this Arm
Study NCT04174937 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PA
Description: Intervention is administered to patients in this Arm
Study NCT03271671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAVA during Non invasive ventilation
Description: NIV during respiratory failure
Study NCT03271671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV during Non invasive ventilation
Description: PSV during respiratory failure
Study NCT00760812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Social Interaction Project- PII
Description: The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
Study NCT00760812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Social Interaction Project- IES
Description: The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
Study NCT03011541 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arm 1
Description: Procedure/ Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
Study NCT00506714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single point cane
Description: Adjustable single point cane with SureGrip handle
Study NCT02371668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261
Description: 50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
Study NCT00601133 — intervention group
Intervention type: OTHER
Intervention: Walking Test
Description: Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later
Study NCT00601133 — intervention group
Intervention type: OTHER
Intervention: Balance Test
Description: Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
Study NCT00601133 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
Study NCT02371668 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
Study NCT03646149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Housing Skills Training Group
Description: 12-session social skills training group for persons with homeless experiences and serious mental illness delivered once a week for 12 weeks
Study NCT04220099 — intervention group
Intervention type: PROCEDURE
Intervention: Electroconvulsive therapy(ECT)
Description: Patients recieve 8-sessions ECT treatments and those kinds of drugs they take since they were recruited remain unchanged during this study.
Study NCT00777192 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
Study NCT02991014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: researcher-selected frequency-modulated music
Description: Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
Study NCT02991014 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: researcher-selected non-modulated music
Description: The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
Study NCT02991014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: participant-selected non-modulated music
Description: Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
Study NCT01192724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: 100 mg BID, for 3 months
Study NCT01192724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg QD, for 1 year
Study NCT01192724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg QD, for 1 year
Study NCT00577005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
Study NCT00577005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00889187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Short-Course Photon Radiation
Study NCT00889187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT03986554 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Videofluoroscopic swallow study
Description: The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
Study NCT03986554 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pharyngeal High Resolution Manometry
Description: This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (\< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
Study NCT00970515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh hernia repair
Description: The mesh is intraperitoneal
Study NCT00970515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open anterior approach
Description: The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
Study NCT01612507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg Ceftaroline fosamil
Description: 1 h infusion
Study NCT01612507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 h infusion
Study NCT01612507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg Ceftaroline fosamil
Description: 2 h infusion
Study NCT01612507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 h infusion
Study NCT03859180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused breathing
Description: Focused breathing is a series of focused, controlled breaths that aid in relaxation. Each participation in this group will be taught how to do focused breathing by the study investigator. Once determined to be able to perform focused breathing, participants will be asked to practice it for 4 minutes, twice a day, for 6 weeks. If they choose to do so, they may practice focused breathing if they become anxious at other times. They will be asked to keep a diary of each time they practice and/or use focused breathing.
Study NCT00956488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
Study NCT01600599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: intravenous 1g and topical 1g
Study NCT01600599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 100mls of topical saline
Study NCT00308750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
Study NCT00308750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease
Study NCT00308750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2, IV, q 21 days, six 21 day cycles or progressive disease
Study NCT00308750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
Study NCT00308750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
Study NCT02810171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
Study NCT02810171 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation Therapy
Description: An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.
Study NCT04562220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine conventional physical therapy plus Vibration session
Description: Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
Study NCT04562220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine conventional physical therapy
Description: Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: 100 mg capsule coadministered orally with ATV or DRV once daily with food
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: 300 mg capsule administered orally once daily with food
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: 800 mg tablet administered orally once daily with food
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: 150 mg tablet coadministered orally with ATV or DRV once daily with food
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV/co
Description: 300/150 mg FDC tablet administered orally once daily with food
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/co
Description: 800/150 mg FDC tablet administered orally once daily with food
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg FDC tablet administered orally once daily without regard to food
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Description: 600/300 mg tablet administered orally once daily with or without regard to food
Study NCT02603107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food
Study NCT02897167 — intervention group
Intervention type: GENETIC
Intervention: Retrospective study of frozen samples
Description: Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
Study NCT02897167 — intervention group
Intervention type: GENETIC
Intervention: Prospective study of fresh samples
Description: Samples of serum and cells will be drawn.
Study NCT03402230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout/Broccoli Seed Extract Supplement
Description: Given PO
Study NCT03402230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03402230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01828216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home sleep study
Description: The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
Study NCT01828216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional polysomnography
Description: conventional type I sleep study according to international guidelines
Study NCT03944993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields Therapy (Dominant leg)
Description: Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
Study NCT03944993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields Therapy (Non-dominant leg)
Description: Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their non-dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
Study NCT03944993 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy (Control)
Description: Participants of this arm will be not be exposed to the fields. Sham treatment will utilise the same PEMF apparatus for 10 minutes, but in non-operational mode, which is indistinguishable from when the apparatus is in operation. Duration of intervention is 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
Study NCT05035849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin and acarbose
Description: One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
Study NCT04627961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
Study NCT00824434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element™
Description: Drug eluting coronary stent system
Study NCT00568334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix (inactivated varicella vaccine)
Description: subcutaneously injection
Study NCT02638376 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)
Description: KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.